JOC The Journal of Organic Chemistry

Cite This: J. Org. Chem. XXXX, XXX, XXX−XXX

Note

pubs.acs.org/joc

Synthesis of Azolo[1,3,5]triazines via Rhodium(III)-Catalyzed Annulation of *N*-Azolo Imines and Dioxazolones

Gia L. Hoang, Kim Søholm Halskov, and Jonathan A. Ellman*

Department of Chemistry, Yale University, 225 Prospect Street, New Haven, Connecticut 06520, United States

Supporting Information

ABSTRACT: A wide range of azolo[1,3,5]triazines were obtained by Rh(III)-catalyzed annulation of *N*-azolo imines and dioxazolones. The reaction proceeds by the first catalytic C−H amidation of an imidoyl C−H bond followed by cyclodehydration. Good yields were obtained for *N*-azolo imines derived from aminoazoles and aromatic and heteroaromatic aldehydes. A range of dioxazolone amidating reagents were employed to introduce aryl, heteroaryl, and alkyl substituents. The reaction was also performed with a benchtop setup at 1 mmol scale using microwave heating.



Bridgehead *N*-fused [5,6]-bicyclic heterocycles are privileged pharmacophores in drug discovery and are present in numerous U.S. FDA approved drugs and many clinical candidates.[1,2] We have recently reported the first examples of Rh(III)-catalyzed imidoyl C−H activation of *N*-azolo imines **1** enabling annulations with alkynes, diazoketones, and sulfoxonium ylides to give azolopyrimidines **2** (Scheme 1A).[3,4] The straightforward one-step preparation of diverse *N*-azolo imine starting materials **1** by simple condensation of readily available aminoazoles with the enormous range of commercially available aromatic and heteroaromatic aldehydes is an important practical aspect of this method. Given that diverse *N*-azolo imines **1** can readily be accessed, we are extensively pursuing different types of transition-metal-catalyzed imidoyl C−H functionalization of **1** for heterocycle synthesis, including for the preparation of other subclasses having the privileged *N*-fused [5,6]-bicyclic heterocycle framework.

Scheme 1. Preparation of Bridgehead *N*-Fused [5,6]-Bicyclic Heterocycles via Catalytic C−H Functionalization



The 1,4,2-dioxazol-5-one amidating reagents **4** were initially identified by Sauer and Mayer in the late 1960s as a safe alternative to acyl azides for *N*-acyl nitrene formation.[5] This elegant finding was subsequently applied to direct C−N bond formation by Dubé[6] and Bolm.[7] Chang and co-workers later on introduced and developed 1,4,2-dioxazol-5-ones as extremely efficient amidating reagents in C−H functionalization reactions.[8] These reagents have now been employed by a number of laboratories for C−H amidation.[9] In work relevant to *N*-fused [5,6]-bicyclic heterocycle synthesis, we recently reported that C-alkenyl azoles **3** could be amidated with 1,4,2-dioxazol-5-ones **4** to afford azolopyrimidines **5** after cyclodehydration (Scheme 1B).[10] Cheng and co-workers have also recently reported that tricyclic or higher order derivatives can be obtained by annulations with 2-arylimidazoles.[11] Herein, we describe Rh(III)-catalyzed imidoyl C−H amidation followed by cyclodehydration of readily available *N*-azolo imines **1** with 1,4,2-dioxazol-5-ones **4** having diverse electronic and steric properties to give azolo[1,3,5]triazines **6** (Scheme 1C), which have been recognized as privileged scaffolds in medicinal chemistry.[12]

Annulation of *N*-azolo imine **1a** and dioxazolone **4a** provided azolotriazine **6aa** in good yield using the cationic Rh(III) catalyst $[Cp^*Rh(MeCN)_3](SbF_6)_2$ with NaOAc and pivalic acid (PivOH) as additives in dioxane at 120 °C (entry

Received: May 15, 2018

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX−XXX

1, Table 1). Under these conditions, complete consumption of the starting imine **1a** was observed and no significant

Table 1. Reaction Parameters for Annulations to Azolotriazines 6[a]



entry	imine	variation	yield[b] (%)
1	**1a**	none	75 (73)[c]
2	**1a**	$[Cp^*RhCl_2]_2$, $AgSbF_6$[d]	60
3	**1a**	$[Cp^*RhCl_2]_2$ (5 mol %)	8
4	**1a**	no Rh	0
5	**1a**	no PivOH	12
6	**1a**	no NaOAc	16
7	**1a**	NaOAc (1 equiv)	79
8	**1a**	100 °C	70
9	**1a**	0.2 M	46
10	**1a**	toluene as solvent	11
11	**1a**	DCE as solvent	9
12	**1a**	MeCN as solvent	25
13	**1a**	$[Cp^*IrCl_2]_2$, $AgSbF_6$[d]	10
14	**1a**	$[Cp^*Co(MeCN)_3](SbF_6)_2$	0
15	**1b**	none	53 (55)[e]
16	**1b**	NaOAc (1 equiv)	37
17	**1b**	100 °C	43

[a]Conditions: **1** (0.10 mmol), **4a** (0.15 mmol), 0.1 M, 16 h. [b]Yield determined by ^1H NMR relative to 1,3,5-trimethoxybenzene as the external standard. [c]Isolated yield of a 0.30 mmol scale (see Scheme 2). [d]$[Cp^*MCl_2]_2$ (5 mol %) and $AgSbF_6$ (20 mol %). [e]Isolated yield of a 0.30 mmol scale (see Scheme 3).

byproducts were detected. An active cationic catalyst could also be formed *in situ* from $[Cp^*RhCl_2]_2$ and $AgSbF_6$ but provided a slightly lower yield of product (entry 2). When the halide was not abstracted from $[Cp^*RhCl_2]_2$, only trace amounts of product were observed (entry 3). As expected, product was not obtained when a Rh(III) catalyst was not added (entry 4). Both PivOH and NaOAc are essential for C–H amidation and cyclodehydration to azolotriazine **6aa**. When either additive was excluded, only a small amount of **6aa** was obtained but with no remaining imine (entries 5 and 6).[13] When stoichiometric NaOAc was used, a comparable yield of **6aa** was obtained (entry 7); however, a substoichiometric quantity of NaOAc was found to be more general (*vide infra*). Lowering the temperature to 100 °C led to a slight reduction in yield (entry 8). Doubling the concentration resulted in a significantly lower yield (entry 9), as did performing the reaction in toluene, DCE, or MeCN (entries 10–12). In comparison to Cp*Rh(III) catalysis, Cp*Ir(III) and Cp*Co(III) catalysts were ineffective and provided little to no product under the same reaction conditions (entries 13 and 14). The optimal conditions were also effective for furfural-derived imine **1b** (entry 15). In contrast to imine **1a**, furfural-derived imine **1b** is more sensitive to the stoichiometry of the NaOAc additive. When 1 equiv rather than 0.5 equiv was used, a lower yield was observed (entry 16). Lowering the temperature to 100 °C also resulted in a lower yield (entry 17).

Using the optimal reaction conditions, we explored the scope of dioxazolone **4** for annulations with *N*-imidazo imine **1a** (Scheme 2). A series of 3-aryl-substituted 1,4,2-dioxazol-5-

Scheme 2. Dioxazolone Scope for Rh(III)-Catalyzed Annulation to Give Azolotriazines 6[a]



[a]Standard conditions as shown. [b]NaOAc (1 equiv) was used.

ones **4a–g** with different electronic properties were effective under the standard conditions, giving bicyclic products **6aa–6ag** in moderate to good yields (46–73%). Thiophene-containing dioxazolone (**4h**) was also a good coupling partner affording product **6ah** in 58% yield. A variety of alkyl-substituted dioxazolones including *n*-alkyl (**4i**), methyl (**4j**), *α*-branched (**4k**), and benzyl (**4l**) served as effective inputs in the coupling reactions providing **6ai–6al** in good to excellent yields (66–82%).

We next investigated the scope for the *N*-azolo imines **1** derived from several different aminoazoles and various aromatic and heteroaromatic aldehydes (Scheme 3). As indicated in the optimization studies, furfural-derived imine **1b** coupled with 3-phenyl-substituted 1,4,2-dioxazol-5-one **4a** to generate heterocycle **6ba** (55%). The same imine coupled equally well with alkyl-substituted dioxazolone **4i** to afford **6bi** in 58% yield. In addition to **1a**, a series of imines derived from 2-amino-imidazole and benzaldehydes bearing electron-deficient (**1c**, **1d**, and **1f**) and electron-rich (**1e**) substituents at the *para*- and *meta*-positions efficiently coupled with both aryl- and alkyl-substituted dioxazolones under standard conditions to give bicyclic heterocycles **6ca–6fi** (59–77%). *Ortho*-substituted benzaldimine **1g** also coupled to give azolotriazine **6gi**, albeit with a slight reduction in yield (46%). Significantly, the bromo- (**1f**) and chloro- (**1g**) substituted imines afforded products that are amenable to subsequent cross-coupling chemistry. Annulations of *N*-azolo imines **1** from enolizable aldehydes were not investigated because this type of imine was difficult to prepare.

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX–XXX

Scheme 3. *N*-Azolo Imine Scope for Rh(III)-Catalyzed Annulations to Give Azolotriazines 6[a]



[a]Standard conditions as shown. [b]NaOAc (1 equiv) was used. [c]DCE (100 °C) was used instead of dioxane (120 °C).

Imine **1h** with dimethyl substitution on the imidazole ring was also an effective coupling partner to give imidazotriazine **6hi**. Although imines derived from 3-aminopyrazoles were not effective coupling partners (data not shown), *N*-triazolo imines **1i** and **1j** afforded triazolotriazines **6ii** and **6ji** in reasonable yields (56–57%). It is notable that imine **1j** with multiple potential sites for directed C–H functionalization was still selective for imidoyl C–H activation to give **6ji**.

Lastly, **6ai** was prepared on the benchtop at 1 mmol scale (Scheme 4). For practical purposes, the reaction was performed using a microwave reactor with a 2 h reaction time. Bicyclic product **6ai** was isolated in reasonable yield (65%).

A possible mechanism for the annulation is depicted in Scheme 5. On the basis of our previous study on annulations of *N*-azolo imines with alkynes, diazoketones, and sulfoxonium ylides,[3] we propose that imine **1** undergoes concerted

Scheme 4. Bench-Top Reaction Setup on a 1 mmol Scale



Scheme 5. Proposed Mechanism for Annulation



metalation–deprotonation to give rhodacycle **A**. In our previously published report,[3] a rhodacycle obtained by imidoyl C–H activation was rigorously characterized by X-ray crystallography and was shown to be competent in the catalytic cycle. In accord with Chang's detailed mechanistic studies on dioxazolone-mediated C–H amidation,[8a] insertion of the *N*-acyl nitrene with release of CO_2 then generates the six-membered rhodacycle **B**. Proto-demetalation affords amide **C** to regenerate the active Rh(III) catalyst. Under the reaction conditions, amide **C** undergoes cyclodehydration to provide the bicyclic heterocycle product **6**.

In conclusion, Rh(III)-catalyzed imidoyl C–H amidation of imines **1** followed by cyclodehydration affords azolotriazines **6**. The reaction proceeds in good yields for a range of aryl, heteroaryl, benzyl, and alkyl dioxazolones **4**. *N*-Azolo imines **1** derived from amino imidazoles and triazoles and a variety of different aromatic and heteroaromatic aldehydes are also effective inputs. Moreover, the reaction is applicable to a straightforward benchtop setup at 1 mmol scale using microwave heating.

EXPERIMENTAL SECTION

General Information. Unless otherwise noted, all commercially available reagents were purchased and used as received. Solvents including 1,4-dioxane, toluene, 1,2-dichloroethane (DCE), and acetonitrile (MeCN) were deoxygenated by sparging with argon and stored over activated 3 Å molecular sieves in a nitrogen filled glovebox. The microwave reaction was performed using a microwave reactor with an external IR sensor and in a closed reaction vessel. Commercial $AgSbF_6$ was stored in a nitrogen filled glovebox. ^1H, ^{13}C, and ^{19}F NMR spectra were recorded on 400, 500, or 600 MHz spectrometers. The chemical shift [δ (ppm)], coupling constants [J (Hz)], multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, pent = pentet, m = multiplet, br = broad), and integration are reported. Chemical shifts for ^1H and ^{13}C NMR are reported relative to residual undeuterated solvent in $CDCl_3$ (7.24 ppm for ^1H NMR and 76.99 ppm for ^{13}C NMR) and $(CD_3)_2SO$ (2.47 ppm for ^1H NMR and 39.94 ppm for ^{13}C NMR). Flash chromatography was carried out with slica gel with 40–63 μm particle size and with 230–400 mesh. Partial data are provided for IR spectra. Melting points are reported uncorrected. High-resolution mass spectra (HRMS) were obtained using electrospray ionization (ESI) on a time-of-flight (TOF) mass spectrometer (Yale University) or electron ionization (EI^+) obtained by University of Illinois SCS Mass Spectrometry Laboratory.

Preparation of Catalysts and Reactants. [Cp*Rh-$(MeCN)_3(SbF_6)_2$] was synthesized according to literature procedures.[8a] *N*-Azolo imine substrates **1a–g** were synthesized according to literature procedures.[3,14] Dioxazolones **4a–h** and **4j–l** were synthesized according to literature procedures.[8a,11,15] Imine **1h** was

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX–XXX

prepared via literature procedures[14] with slight modification. Imines **1i** and **1j** were synthesized as described below. Dioxazolone **4i** was prepared according to a literature procedure with slight modification.[8a]

*(E)-N-(4,5-Dimethyl-1H-imidazol-2-yl)-1-phenylmethanimine (**1h**).* Imine **1h** was prepared via literature procedures[14] with slight modification. To a flame-dried 50 mL round-bottom flask was added 2-amino-4,5-dimethylimidazole ethyl sulfate[16] (1.9 g, 8.0 mmol, 1.0 equiv). The flask was degassed and filled with nitrogen. To the flask was added CH_2Cl_2 (10 mL) and then benzaldehyde (0.81 mL, 8.0 mmol, 1.0 equiv), $Ti(OiPr)_4$ (3.79 mL, 12.8 mmol, 1.60 equiv), and Et_3N (4.46 mL, 32.0 mmol, 4.00 equiv) were sequentially added dropwise. The resultant mixture was stirred overnight at rt, and the reaction was quenched with water (20 mL). The resulting mixture was immediately filtered and washed with CH_2Cl_2. The filtrate was transferred to a separatory funnel. The organic layer was separated, and the aqueous layer was washed with CH_2Cl_2 (×2). The combined organic extracts were dried (anhyd. Na_2SO_4) and concentrated under reduced pressure. Purification by silica gel column chromatography (20−40% ethyl acetate/hexanes) afforded **1h** (814 mg, 51%) as a yellow solid. mp 199−201 °C. FTIR (neat) 2918, 1600, 1572, 1450, 1431, 1246, 872, 755, 685, 561, 494 cm^{-1}. ^1H NMR (600 MHz, $CDCl_3$) δ 10.07 (s, 1H), 9.22 (s, 1H), 7.85 (d, J = 6.7 Hz, 2H), 7.47−7.34 (m, 3H), 2.17 (s, 3H), 2.03 (s, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 158.6, 148.1, 135.7, 132.9, 131.5, 129.0, 128.8, 121.7, 12.5, 9.5. HRMS (EI$^+$): m/z $[M-H]^+$ calcd for $C_{12}H_{12}N_3$, 198.1031; found 198.1029.

*(E)-N-(3-Methyl-1H-1,2,4-triazol-5-yl)-1-phenylmethanimine (**1i**).* Inside a glovebox, to a flame-dried 10−20 mL Biotage microwave vial (#354833) was added 3-methyl-1*H*-1,2,4-triazol-5-amine (441 mg, 4.50 mmol, 1.00 equiv), benzaldehyde (0.460 mL, 4.50 mmol, 1.00 equiv), 3 Å molecular sieves (approximately 7.5 g), and THF (20.0 mL). The vial was capped with a Teflon-lined cap and removed from the glovebox, and the mixture was stirred with a preheated stem block filled with oil at 100 °C overnight. The resulting mixture was filtered through a pad of Celite, washed with ethyl acetate, and concentrated under reduced pressure. The crude residue was recrystallized with hot ethyl acetate to afford **1i** (621 mg, 74%) as a white solid. mp 139−141 °C. FTIR (neat) 1622, 1558, 1450, 1314, 1220, 1149, 1063, 878, 763, 687, 544, 496 cm^{-1}. ^1H NMR (600 MHz, $CDCl_3$) δ 13.49 (s, 1H), 9.30 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 7.2 Hz, 1H), 7.45 (t, J = 7.4 Hz, 2H), 2.59 (s, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 165.0, 164.4, 155.6, 135.3, 132.4, 129.5, 128.9, 13.0. HRMS (EI$^+$): m/z $[M-H]^+$ calcd for $C_{10}H_9N_4$, 185.0827; found 185.0824.

*(E)-1-Phenyl-N-(3-phenyl-1H-1,2,4-triazol-5-yl)methanimine (**1j**).* Inside a glovebox, to a flame-dried 2−5 mL Biotage microwave vial (#351521) was added 3-phenyl-1*H*-1,2,4-triazol-5-amine (801 mg, 5.00 mmol, 1.00 equiv), benzaldehyde (0.510 mL, 5.00 mmol, 1.00 equiv), 3 Å molecular sieves (approximately 200 mg), and toluene (2.00 mL). The vial was capped with a Teflon-lined cap and removed from the glovebox, and the mixture was stirred with a preheated stem block filled with oil at 100 °C overnight (*Note:* a white solid precipitated out of the reaction mixture after about 2 h). The solid was scraped off, transferred to a filtered frit, and washed thoroughly with ethyl acetate. The resulting solid (mixed with molecular sieves) was dissolved with hot chloroform and filtered through a pad of Celite. The filtrate was then concentrated under reduced pressure to afford **1j** (992 mg, 80%) as a white solid. mp 169−172 °C. FTIR (neat) 1618, 1564, 1472, 1381, 1219, 1158, 987, 770, 694, 572, 509 cm^{-1}. ^1H NMR (600 MHz, $(CD_3)_2SO$) δ 9.30 (s, 1H), 8.07−8.00 (m, 4H), 7.60−7.42 (m, 6H). ^{13}C NMR (151 MHz, $(CD_3)_2SO$) δ 164.9, 163.3, 157.7, 135.6, 133.0, 130.1, 129.8, 129.5, 129.3, 126.3. HRMS (EI$^+$): m/z $[M-H]^+$ calcd for $C_{15}H_{11}N_4$, 247.0984; found 247.0984.

*3-(3-Phenylpropyl)-1,4,2-dioxazol-5-one (**2i**).* The starting hydroxamic acid (*N*-hydroxy-4-phenylbutanamide) was prepared according to a literature procedure for a related compound.[17] To a flame-dried 100 mL round-bottom flask was added 4-phenylbutanoic acid (4.43 g, 27.0 mmol, 1.00 equiv) and THF (45.0 mL). After adding carbonyldiimidazole (CDI) (6.57 g, 40.5 mmol, 1.50 equiv), the reaction mixture was stirred under nitrogen at rt for 1 h, and then, hydroxylamine chloride (3.75 g, 54.0 mmol, 2.00 equiv) was added. After an overnight stir at rt, the resultant mixture was transferred to a separatory funnel, diluted with aqueous $KHSO_4$ (300 mL), and extracted with ethyl acetate (3 × 100 mL). The combined organic extracts were washed with brine, dried (anhyd. Na_2SO_4), and concentrated under reduced pressure to afford crude *N*-hydroxy-4-phenylbutanamide (4.9 g, quantitative) as a white solid, which was used in the next step without further purification.

Dioxazolone **4i** was prepared via a literature procedure for a related compound.[8a] The above crude *N*-hydroxy-4-phenylbutanamide (4.85 g, 27.0 mmol, 1.00 equiv) was redissolved in CH_2Cl_2 (300 mL). After adding CDI (4.38 g, 27.0 mmol, 1.00 equiv), the reaction mixture was stirred under nitrogen at rt for 30 min and quenched with 1 N HCl (150 mL). The resulting mixture was transferred to a separatory funnel, and the organic layer was separated. The aqueous layer was extracted with CH_2Cl_2 (×2). The combined organic extracts were dried (anhyd. Na_2SO_4) and concentrated under reduced pressure. Purification by silica gel column chromatography (10% ethyl acetate/hexanes) afforded **4i** (5.03 g, 91%) as a colorless liquid. FTIR (neat) 1871, 1824, 1636, 1148, 981, 752, 699 cm^{-1}. ^1H NMR (500 MHz, $CDCl_3$) δ 7.32 (t, J = 7.5 Hz, 2H), 7.23 (t, J = 7.4 Hz, 1H), 7.18 (d, J = 6.9 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 2.62 (t, J = 7.5 Hz, 2H), 2.07 (p, J = 7.4 Hz, 2H). ^{13}C NMR (126 MHz, $CDCl_3$) δ 166.4, 154.1, 139.7, 128.7, 128.4, 126.5, 34.5, 25.9, 24.0. HRMS (EI$^+$): m/z $[M]^+$ calcd for $C_{11}H_{11}O_3N$, 205.0739; found 205.0742.

General Procedures for C−H Functionalization of *N*-Azolo Imines with 3-Substituted 1,4,2-Dioxazol-5-ones (0.3 mmol Scale). To a flame-dried 2−5 mL Biotage microwave vial (#351521) charged with a stir bar in a glovebox was added *N*-azolo imine (0.300 mmol, 1.00 equiv), 3-substituted 1,4,2-dioxazol-5-one (0.450 mmol, 1.50 equiv), $[Cp^*Rh(MeCN)_3](SbF_6)_2$ (10 mol %, 0.0300 mmol, 25.0 mg), PivOH (0.600 mmol, 2.00 equiv, 61.2 mg), NaOAc (0.150 mmol, 0.500 equiv, 12.3 mg), and dioxane (0.100 M, 3.00 mL). The vial was capped with a Teflon-lined cap and removed from the glovebox, and the mixture was stirred with a preheated stem block filled with oil at 120 °C for 16 h. The resultant mixture was then cooled to rt, filtered through a pad of Celite, washed thoroughly with acetone, and concentrated under reduced pressure. The product was purified by silica gel column chromatography.

*2,4-Diphenylimidazo[1,2-a][1,3,5]triazine (**6aa**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 73.4 mg of 3-phenyl-1,4,2-dioxazol-5-one **4a**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6aa** (59.9 mg, 73%) as a yellow solid. mp 156−158 °C. FTIR (neat) 1593, 1572, 1477, 1391, 1329, 1257, 1132, 759, 737, 687, 607, 479 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.72−8.55 (m, 2H), 8.09 (d, J = 6.6 Hz, 2H), 7.84−7.76 (m, 2H), 7.72−7.60 (m, 3H), 7.53−7.46 (m, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.6, 155.1, 150.7, 136.6, 135.8, 132.6, 131.8, 131.6, 129.2, 128.8, 128.7, 128.5, 109.1. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{17}H_{13}N_4^+$, 273.1135; found 273.1121.

*4-(4-Chlorophenyl)-2-phenylimidazo[1,2-a][1,3,5]triazine (**6ab**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 88.9 mg of 3-(4-chlorophenyl)-1,4,2-dioxazol-5-one **4b**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6ab** (55.1 mg, 60%) as a yellow solid. mp >200 °C. FTIR (neat) 3171, 3099, 1605, 1589, 1565, 1471, 1367, 1330, 1254, 1131, 1064, 731, 685, 485 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.70−8.53 (m, 2H), 8.06 (d, J = 8.6 Hz, 2H), 7.84−7.74 (m, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.54−7.44 (m, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.5, 154.0, 150.7, 139.1, 136.9, 135.6, 131.7, 130.1, 130.1, 129.6, 128.7, 128.6, 108.8. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{17}H_{12}ClN_4^+$, 307.0745; found 307.0736.

*2-Phenyl-4-(4-(trifluoromethyl)phenyl)imidazo[1,2-a][1,3,5]-triazine (**6ac**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 104 mg of 3-(4-(trifluoromethyl)phenyl)-1,4,2-dioxazol-5-one **4c**. Purification by

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX−XXX

silica gel column chromatography (10−30% acetone/hexanes) afforded **6ac** (47.1 mg, 46%) as a yellow solid. mp 158−161 °C. FTIR (neat) 1593, 1571, 1479, 1390, 1324, 1254, 1168, 1110, 1064, 1014, 848, 768, 716, 687, 440 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.68−8.52 (m, 2H), 8.22 (d, J = 8.1 Hz, 2H), 7.92 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 1.7 Hz, 1H), 7.75 (d, J = 1.6 Hz, 1H), 7.54−7.44 (m, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.5, 153.7, 150.5, 137.1, 135.5, 135.1, 134.3 (q, J = 33.1 Hz), 131.8, 129.2, 128.8, 128.6, 126.3 (q, J = 3.7 Hz), 123.4 (q, J = 272.9 Hz), 108.7. ^{19}F NMR (376 MHz, $CDCl_3$) δ −63.19. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{18}H_{12}F_3N_4^+$, 341.1009; found 341.1010.

*4-(4-Methoxyphenyl)-2-phenylimidazo[1,2-a][1,3,5]triazine (**6ad**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 86.9 mg of 3-(4-methoxyphenyl)-1,4,2-dioxazol-5-one **4d**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6ad** (64.6 mg, 71%) as a yellow foam. FTIR (neat) 1574, 1501, 1473, 1391, 1329, 1260, 1246, 1132, 1038, 766, 713, 687, 611 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.65−8.56 (m, 2H), 8.08 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 1.7 Hz, 1H), 7.75 (d, J = 1.7 Hz, 1H), 7.52−7.43 (m, 3H), 7.10 (d, J = 8.9 Hz, 2H), 3.91 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 163.1, 159.5, 154.7, 150.9, 136.4, 136.0, 131.4, 130.7, 128.7, 128.5, 123.9, 114.5, 109.0, 55.6. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{18}H_{15}N_4O^+$, 303.1240; found 303.1242.

*4-(3-Bromophenyl)-2-phenylimidazo[1,2-a][1,3,5]triazine (**6ae**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 109 mg of 3-(3-bromophenyl)-1,4,2-dioxazol-5-one **4e**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6ae** (64.2 mg, 61%) as a yellow solid. mp 147−150 °C. FTIR (neat) 3167, 3133, 3104, 3063, 1588, 1562, 1464, 1389, 1327, 1253, 1131, 901, 869, 765, 731, 688, 609 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.69−8.55 (m, 2H), 8.22 (t, J = 1.8 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.84−7.78 (m, 2H), 7.77 (d, J = 1.6 Hz, 1H), 7.56−7.46 (m, 4H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.5, 153.6, 150.5, 136.9, 135.6, 135.5, 133.6, 131.8, 131.7, 130.7, 128.8, 128.6, 127.1, 123.4, 108.9. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{17}H_{12}BrN_4^+$, 351.0240; found 351.0238.

*4-(3-Methoxyphenyl)-2-phenylimidazo[1,2-a][1,3,5]triazine (**3af**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 86.9 mg of 3-(3-methoxyphenyl)-1,4,2-dioxazol-5-one **4f**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6af** (59.2 mg, 65%) as a yellow foam. FTIR (neat) 1574, 1501, 1473, 1391, 1329, 1289, 1260, 1246, 1132, 1038, 766, 713, 687, 611 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.67−8.57 (m, 2H), 7.83−7.75 (m, 2H), 7.66−7.44 (m, 6H), 7.19 (dd, J = 8.3, 1.9 Hz, 1H), 3.91 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 160.1, 159.6, 155.0, 150.6, 136.5, 135.8, 132.9, 131.6, 130.3, 128.8, 128.5, 120.7, 118.3, 114.4, 109.2, 55.6. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{18}H_{15}N_4O^+$, 303.1240; found 303.1242.

*4-(2-Chlorophenyl)-2-phenylimidazo[1,2-a][1,3,5]triazine (**6ag**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 88.9 mg of 3-(2-chlorophenyl)-1,4,2-dioxazol-5-one **4g**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6ag** (43.1 mg, 47%) as a tan solid. mp 156−158 °C. FTIR (neat) 1603, 1584, 1500, 1462, 1399, 1329, 1251, 1135, 1026, 763, 712, 690, 607, 438 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.67−8.52 (m, 2H), 7.76 (d, J = 1.6 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.65−7.57 (m, 2H), 7.56−7.44 (m, 4H), 7.23 (d, J = 1.7 Hz, 1H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.3, 153.7, 149.6, 136.6, 135.7, 132.7, 132.7, 131.6, 130.9, 130.7, 130.6, 128.9, 128.6, 127.6, 109.5. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{17}H_{12}ClN_4^+$, 307.0745; found 307.0754.

*2-Phenyl-4-(thiophen-2-yl)imidazo[1,2-a][1,3,5]triazine (**6ah**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 76.1 mg of 3-(2-thiophenyl)-1,4,2-dioxazol-5-one **4h**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6ah** (48.3 mg, 58%) as a yellow solid. mp 141−144 °C. FTIR (neat) 3143, 3093, 1580, 1531, 1468, 1425, 1329, 1254, 1131, 862, 761, 706, 683, 480 cm^{-1}. ^1H NMR (600 MHz, $CDCl_3$) δ 8.65−8.58 (m, 2H), 8.15 (d, J = 3.8 Hz, 1H), 8.01 (d, J = 1.6 Hz, 1H), 7.86 (d, J = 1.6 Hz, 1H), 7.78 (d, J = 4.9 Hz, 1H), 7.54−7.45 (m, 3H), 7.31 (t, J = 4.4 Hz, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 159.0, 151.1, 148.9, 137.3, 135.7, 135.1, 133.6, 132.0, 131.5, 128.8, 128.7, 128.5, 108.9. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{15}H_{11}N_4S^+$, 279.0699; found 279.0698.

*2-Phenyl-4-(3-phenylpropyl)imidazo[1,2-a][1,3,5]triazine (**6ai**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 92.3 mg of 3-(3-phenylpropyl)-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (5−35% acetone/hexanes) afforded **6ai** (75.6 mg, 80%) as an off-white solid. mp 121−123 °C. FTIR (neat) 3104, 2930, 1592, 1501, 1400, 1259, 1141, 747, 705, 697, 621, 501 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.68−8.49 (m, 2H), 7.72 (apparent s, 1H), 7.53−7.44 (m, 3H), 7.34 (d, J = 1.6 Hz, 1H), 7.33−7.18 (m, 5H) 3.07 (t, J = 7.4 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.38 (p, J = 7.4 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.1, 158.0, 149.7, 140.7, 136.3, 135.9, 131.5, 128.74, 128.6, 128.5, 128.5, 126.3, 107.2, 35.0, 32.3, 26.1. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{20}H_{19}N_4^+$, 315.1604; found 315.1605.

*4-Methyl-2-phenylimidazo[1,2-a][1,3,5]triazine (**6aj**).* The reaction was performed according to the general procedure with slight modification (1 equiv (24.6 mg) of NaOAc was used) employing 51.4 mg of *N*-imidazo imine **1a** and 45.5 mg of 3-methyl-1,4,2-dioxazol-5-one **4j**. Purification by silica gel column chromatography (10−35% acetone/hexanes) afforded **6aj** (43.1 mg, 68%) as a yellow solid. mp >200 °C. FTIR (neat) 1605, 1592, 1503, 1432, 1261, 1145, 768, 717, 707, 685, 542 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.65−8.47 (m, 2H), 7.75 (d, J = 1.6 Hz, 1H), 7.52−7.45 (m, 3H), 7.44 (d, J = 1.6 Hz, 1H), 2.87 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.3, 155.4, 149.6, 136.3, 135.8, 131.5, 128.7, 128.5, 107.6, 20.8. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{12}H_{11}N_4^+$, 211.0978; found 211.0976.

*4-Isopropyl-2-phenylimidazo[1,2-a][1,3,5]triazine (**6ak**).* The reaction was performed according to the general procedure employing 51.4 mg of *N*-imidazo imine **1a** and 58.1 mg of 3-isopropyl-1,4,2-dioxazol-5-one **4k**. Purification by silica gel column chromatography (5−35% acetone/hexanes) afforded **6ak** (58.4 mg, 82%) as a white solid. mp 102−104 °C. FTIR (neat) 3120, 3097, 2971, 2934, 1606, 1593, 1501, 1402, 1332, 1252, 1126, 771, 739, 692, 619, 525, 483 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.69−8.49 (m, 2H), 7.73 (d, J = 1.7 Hz, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.49−7.42 (m, 3H) 3.40 (hept, J = 6.8 Hz, 1H), 1.51 (d, J = 6.8 Hz, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 162.6, 159.3, 149.9, 136.2, 136.0, 131.4, 128.7, 128.5, 107.3, 32.3, 19.1. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{14}H_{15}N_4^+$, 239.1291; found 239.1292.

*4-Benzyl-2-phenylimidazo[1,2-a][1,3,5]triazine (**6al**).* The reaction was performed according to the general procedure with slight modification (1 equiv (24.6 mg) of NaOAc was used) employing 51.4 mg of *N*-imidazo imine **1a** and 79.7 mg of 3-benzyl-1,4,2-dioxazol-5-one **4l**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6al** (56.5 mg, 66%) as a yellow solid. mp 161−163 °C. FTIR (neat) 1608, 1592, 1498, 1402, 1330, 1133, 909, 732, 703, 686, 623, 563, 537 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.64−8.51 (m, 2H), 7.68 (d, J = 1.7 Hz, 1H), 7.56−7.45 (m, 3H), 7.42 (d, J = 1.7 Hz, 1H), 7.38−7.25 (m, 5H) 4.48 (s, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.3, 156.5, 149.9, 136.4, 135.8, 132.7, 131.5, 129.1, 128.9, 128.8, 128.5, 127.9, 107.8, 40.9. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{18}H_{15}N_4^+$, 287.1291; found 287.1293.

*2-(Furan-2-yl)-4-phenylimidazo[1,2-a][1,3,5]triazine (**6ba**).* The reaction was performed according to the general procedure employing 48.3 mg of *N*-imidazo imine **1b** and 73.4 mg of 3-phenyl-1,4,2-dioxazol-5-one **4a**. Purification by silica gel column chromatography (10−35% acetone/hexanes) afforded **6ba** (43.2 mg, 55%) as a yellow solid. mp 130−132 °C. FTIR (neat) 1567, 1503, 1476, 1446, 1325, 1259, 1132, 759, 740, 694, 631, 594, 465 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.06−7.98 (m, 2H), 7.77−7.74 (m, 2H), 7.70−7.56 (m, 4H), 7.49 (d, J = 3.5 Hz, 1H), 6.59 (dd, J = 3.5, 1.7 Hz, 1H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 155.7, 152.3, 150.8, 149.9, 146.1, 136.7,

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX−XXX

132.7, 131.4, 129.3, 128.7, 115.9, 112.5, 109.3. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{15}H_{11}N_4O^+$, 263.0927; found 263.0929.

*2-(Furan-2-yl)-4-(3-phenylpropyl)imidazo[1,2-a][1,3,5]triazine (**6bi**).* The reaction was performed according to the general procedure employing 48.3 mg of *N*-imidazo imine **1b** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (10−35% acetone/hexanes) afforded **6bi** (53.2 mg, 58%) as a tan solid. mp 117−119 °C. FTIR (neat) 3108, 2925, 2668, 1603, 1583, 1498, 1455, 1414, 1327, 1264, 1166, 1110, 1005, 750, 701, 594, 497 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.70 (d, J = 1.7 Hz, 1H), 7.65 (dd, J = 1.7, 0.9 Hz, 1H), 7.44 (dd, J = 3.5, 0.9 Hz, 1H), 7.35−7.13 (m, 6H), 6.57 (dd, J = 3.5, 1.8 Hz, 1H), 3.05 (t, J = 7.4 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.31 (p, J = 7.5 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.7, 151.9, 150.9, 149.0, 146.1, 140.6, 136.4, 128.6, 128.5, 126.4, 115.8, 112.5, 107.5, 35.0, 32.5, 26.4. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{18}H_{17}N_4O^+$, 305.1397; found 305.1396.

*Methyl 4-(4-Phenylimidazo[1,2-a][1,3,5]triazin-2-yl)benzoate (**6ca**).* The reaction was performed according to the general procedure employing 68.8 mg of *N*-imidazo imine **1c** and 73.4 mg of 3-phenyl-1,4,2-dioxazol-5-one **4a**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6ca** (64.3 mg, 65%) as a yellow solid. mp >200 °C. FTIR (neat) 3160, 3104, 1719, 1612, 1576, 1477, 1283, 1254, 1107, 761, 735, 692 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.70 (d, J = 8.6 Hz, 2H), 8.15 (d, J = 8.5 Hz, 2H), 8.10 (d, J = 6.7 Hz, 2H), 7.89−7.81 (m, 2H), 7.76−7.61 (m, 3H), 3.94 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.7, 158.5, 155.3, 150.4, 139.9, 137.1, 132.8, 132.5, 131.6, 129.7, 129.3, 128.7, 128.6, 109.3, 52.3. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{19}H_{15}N_4O_2^+$, 331.1190; found 331.1191.

*Methyl 4-(4-(3-Phenylpropyl)imidazo[1,2-a][1,3,5]triazin-2-yl)-benzoate (**6ci**).* The reaction was performed according to the general procedure with slight modification (1 equiv (24.6 mg) of NaOAc was used) employing 68.8 mg of *N*-imidazo imine **1c** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6ci** (61.1 mg, 55%) as a white solid. mp 108−110 °C. FTIR (neat) 1721, 1610, 1593, 1504, 1495, 1410, 1273, 1252, 1016, 870, 770, 731, 718, 699 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.64 (d, J = 8.5 Hz, 2H), 8.14 (d, J = 8.5 Hz, 2H), 7.77 (d, J = 1.6 Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H), 7.34−7.15 (m, 5H), 3.94 (s, 3H), 3.10 (t, J = 7.4 Hz, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.40 (p, J = 7.4 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.7, 158.3, 158.0, 149.4, 140.6, 139.9, 136.7, 132.4, 129.7, 128.6, 128.5, 126.4, 107.5, 52.3, 35.0, 32.4, 26.1. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{22}H_{21}N_4O_2^+$, 373.1659; found 373.1657.

*4-Phenyl-2-(4-(trifluoromethyl)phenyl)imidazo[1,2-a][1,3,5]-triazine (**6da**).* The reaction was performed according to the general procedure employing 71.8 mg of *N*-imidazo imine **1d** and 73.4 mg of 3-phenyl-1,4,2-dioxazol-5-one **4a**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6da** (59.8 mg, 59%) as a yellow solid. mp 143−146 °C. FTIR (neat) 1619, 1595, 1573, 1478, 1318, 1257, 1169, 1104, 1064, 1015, 858, 774, 694, 590, 440 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.74 (d, J = 8.1 Hz, 2H), 8.09 (d, J = 7.4 Hz, 2H), 7.84 (d, J = 8.8 Hz, 2H), 7.79−7.58 (m, 5H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.1, 155.4, 150.3, 139.1, 137.1, 132.9 (q, J = 32.6 Hz), 132.9, 131.5, 129.3, 129.0, 128.7, 125.5 (q, J = 3.7 Hz), 124.0 (q, J = 272.4 Hz), 109.4. ^{19}F NMR (376 MHz, $CDCl_3$) δ −62.86. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{18}H_{12}F_3N_4^+$, 341.1009; found 341.1013.

*4-(3-Phenylpropyl)-2-(4-(trifluoromethyl)phenyl)imidazo[1,2-a]-[1,3,5]triazine (**6di**).* The reaction was performed according to the general procedure employing 71.8 mg of *N*-imidazo imine **1d** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6di** (87.8 mg, 77%) as a white solid. mp 96−99 °C. FTIR (neat) 1617, 1595, 1496, 1415, 1319, 1253, 1164, 1107, 1063, 1015, 857, 784, 739, 697, 592, 489 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.68 (d, J = 8.2 Hz, 2H), 7.78 (d, J = 1.6 Hz, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 1.6 Hz, 1H), 7.34−7.26 (m, 2H), 7.26−7.17 (m, 3H), 3.11 (t, J = 7.4 Hz, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.40 (p, J = 7.4 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.4, 157.6, 149.3, 140.5, 139.2, 136.8, 132.8 (q, J = 32.5 Hz), 128.9, 128.6, 128.4, 126.4, 125.5 (q, J = 3.7 Hz), 124.0 (q, J = 272.4 Hz), 107.5, 35.0, 32.4, 26.1. ^{19}F NMR (376 MHz, $CDCl_3$) δ −62.86. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{21}H_{18}F_3N_4^+$, 383.1478; found 383.1480.

*2-(4-Methoxyphenyl)-4-phenylimidazo[1,2-a][1,3,5]triazine (**6ea**).* The reaction was performed according to the general procedure employing 60.4 mg of *N*-imidazo imine **1e** and 73.4 mg of 3-phenyl-1,4,2-dioxazol-5-one **4a**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6ea** (55.1 mg, 61%) as a yellow solid. mp 173−176 °C. FTIR (neat) 1591, 1573, 1500, 1471, 1448, 1391, 1310, 1249, 1165, 1138, 1023, 851, 777, 704, 691, 577, 516 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.57 (d, J = 8.9 Hz, 2H), 8.07 (d, J = 6.8 Hz, 2H), 7.78−7.71 (m, 2H), 7.70−7.59 (m, 3H), 6.98 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 162.6, 159.5, 154.9, 150.8, 136.2, 132.5, 131.9, 130.6, 129.1, 128.7, 128.4, 113.9, 108.9, 55.4. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{18}H_{15}N_4O^+$, 303.1240; found 303.1255.

*2-(4-Methoxyphenyl)-4-(3-phenylpropyl)imidazo[1,2-a][1,3,5]-triazine (**6ei**).* The reaction was performed according to the general procedure employing 60.4 mg of *N*-imidazo imine **1e** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6ei** (64.1 mg, 62%) as a yellow solid. mp 101−104 °C. FTIR (neat) 1593, 1508, 1493, 1399, 1307, 1249, 1165, 1028, 842, 784, 744, 698, 582, 503 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.53 (d, J = 9.0 Hz, 2H), 7.67 (d, J = 1.6 Hz, 1H), 7.34−7.18 (m, 6H), 6.98 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H), 3.05 (t, J = 7.4 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.37 (p, J = 7.4 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 162.5, 159.0, 157.7, 149.9, 140.8, 135.9, 130.6, 128.6, 128.5, 128.5, 126.3, 113.9, 106.9, 55.4, 35.0, 32.3, 26.1. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{21}H_{21}N_4O^+$, 345.1710; found 345.1707.

*2-(3-Bromophenyl)-4-phenylimidazo[1,2-a][1,3,5]triazine (**6fa**).* The reaction was performed according to the general procedure employing 75.0 mg of *N*-imidazo imine **1f** and 73.4 mg of 3-phenyl-1,4,2-dioxazol-5-one **4a**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6fa** (62.2 mg, 59%) as a yellow solid. mp 179−182 °C. FTIR (neat) 1597, 1572, 1504, 1479, 1380, 1324, 1248, 1227, 1131, 1069, 764, 735, 690, 674, 661, 608 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.78 (t, J = 1.9 Hz, 1H), 8.56 (d, J = 7.9 Hz, 1H), 8.14−8.05 (m, 2H), 7.87−7.79 (m, 2H), 7.73−7.59 (m, 4H), 7.36 (t, J = 7.9 Hz, 1H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.1, 155.3, 150.3, 137.9, 136.9, 134.4, 132.8, 131.7, 131.5, 130.1, 129.3, 128.8, 127.3, 122.8, 109.3. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{17}H_{12}BrN_4^+$, 351.0240; found 351.0245.

*2-(3-Bromophenyl)-4-(3-phenylpropyl)imidazo[1,2-a][1,3,5]-triazine (**6fi**).* The reaction was performed according to the general procedure employing 75.0 mg of *N*-imidazo imine **1f** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (10−30% acetone/hexanes) afforded **6fi** (72.1 mg, 61%) as a white solid. mp 100−102 °C. FTIR (neat) 1600, 1495, 1455, 1319, 1253, 1131, 807, 779, 739, 719, 696, 673, 436 cm^{-1}. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.74 (t, J = 1.8 Hz, 1H), 8.50 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 1.6 Hz, 1H), 7.61 (ddd, J = 7.9, 2.1, 1.1 Hz, 1H), 7.43−7.12 (m, 8H), 3.09 (t, J = 7.4 Hz, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.38 (p, J = 7.4 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.3, 157.6, 149.4, 140.6, 138.0, 136.6, 134.3, 131.7, 130.1, 128.6, 128.5, 127.2, 126.4, 122.8, 107.4, 35.0, 32.4, 26.1. HRMS (ESI): m/z [M + H]$^+$ calcd for $C_{20}H_{18}BrN_4^+$, 393.0709; found 393.0708.

*2-(2-Chlorophenyl)-4-(3-phenylpropyl)imidazo[1,2-a][1,3,5]-triazine (**6gi**).* The reaction was performed according to the general procedure with slight modification (1 equiv (24.6 mg) of NaOAc was used) employing 61.7 mg of *N*-imidazo imine **1g** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (5−30% acetone/hexanes) afforded **6gi** (48.3 mg, 46%) as a clear oil. FTIR (neat) 1587, 1495, 1329, 1261, 1247, 1139, 1107, 1049, 910, 761, 735, 698 cm^{-1}. ^{1}H NMR (600 MHz, $CDCl_3$) δ 7.97−7.92 (m, 1H), 7.81 (d, J = 1.6 Hz, 1H), 7.53−7.48 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.41−7.36 (m, 2H), 7.31−7.27 (m, 2H), 7.24−7.17 (m, 3H), 3.11 (t, J = 7.4 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.36 (p, J = 7.4 Hz, 2H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 159.8,

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX−XXX

158.1, 149.0, 140.7, 136.6, 136.0, 133.3, 132.1, 131.0, 130.9, 128.6, 128.5, 126.8, 126.3, 107.3, 34.9, 32.5, 26.2. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{20}H_{18}ClN_4^+$, 349.1215; found 349.1214.

*6,7-Dimethyl-2-phenyl-4-(3-phenylpropyl)imidazo[1,2-a][1,3,5]-triazine (**6hi**).* The reaction was performed according to the general procedure employing 59.8 mg of *N*-imidazo imine **1h** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (10−35% acetone/hexanes) afforded **6hi** (53.5 mg, 52%) as a yellow solid. mp 149−152 °C. FTIR (neat) 1606, 1595, 1495, 1487, 1405, 1264, 1229, 1133, 1022, 756, 737, 697, 565, 487 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.58−8.45 (m, 2H), 7.52−7.43 (m, 3H), 7.34−7.17 (m, 5H), 3.26 (t, J = 7.5 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.49 (s, 3H), 2.35 (s, 3H), 2.30 (p, J = 7.5 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.1, 157.2, 148.6, 143.5, 141.0, 136.1, 131.0, 128.5, 128.4, 128.4, 126.2, 114.0, 34.9, 33.0, 27.9, 13.6, 11.9. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{22}H_{23}N_4^+$, 343.1917; found 343.1918.

*2-Methyl-5-phenyl-7-(3-phenylpropyl)-[1,2,4]triazolo[1,5-a]-[1,3,5]triazine (**6ii**).* The reaction was performed according to the general procedure with slight modification (1 equiv (24.6 mg) of NaOAc was used; DCE was used instead of dioxane; temp = 100 °C) employing 55.9 mg of *N*-triazolo imine **1i** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (10−30% ethyl acetate/hexanes) afforded **6ii** (56.4 mg, 57%) as a white solid. mp 117−120 °C. FTIR (neat) 1610, 1593, 1529, 1478, 1445, 1407, 1376, 1312, 768, 746, 687, 677, 587, 570, 491 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.58 (d, J = 6.8 Hz, 2H), 7.57−7.46 (m, 3H), 7.29−7.15 (m, 5H), 3.35 (t, J = 7.5 Hz, 2H), 2.84 (t, J = 7.6 Hz, 2H), 2.62 (s, 3H), 2.39 (p, J = 7.6 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 167.6, 163.3, 160.1, 157.4, 140.8, 135.2, 132.3, 129.3, 128.7, 128.5, 128.4, 126.2, 35.2, 31.4, 26.5, 15.2. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{20}H_{20}N_5^+$, 330.1713; found 330.1721.

*2,5-Diphenyl-7-(3-phenylpropyl)-[1,2,4]triazolo[1,5-a][1,3,5]-triazine (**6ji**).* The reaction was performed according to the general procedure with slight modification (1 equiv (24.6 mg) of NaOAc was used; DCE was used instead of dioxane; temp = 100 °C) employing 74.5 mg of *N*-triazolo imine **1j** and 92.3 mg of 3-phenyl-1,4,2-dioxazol-5-one **4i**. Purification by silica gel column chromatography (5−10% ethyl acetate/hexanes) afforded **6ji** (65.7 mg, 56%) as a white solid. mp 136−138 °C. FTIR (neat) 1607, 1595, 1527, 1511, 1449, 1410, 1375, 1276, 767, 703, 697, 688, 607, 501 cm^{-1}. ^1H NMR (400 MHz, $CDCl_3$) δ 8.62 (d, J = 6.7 Hz, 2H), 8.40−8.32 (m, 2H), 7.60−7.47 (m, 6H), 7.31−7.15 (m, 5H), 3.43 (t, J = 7.4 Hz, 2H), 2.88 (t, J = 7.5 Hz, 2H), 2.44 (p, J = 7.5 Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.8, 163.3, 160.5, 157.7, 140.9, 135.2, 132.4, 131.1, 129.8, 129.3, 128.7, 128.7, 128.5, 128.4, 127.8, 126.2, 35.2, 31.4, 26.5. HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{25}H_{22}N_5^+$, 392.1870; found 392.1875.

Procedure for C−H Functionalization of *N*-Imidazo Imine 1a with 3-(3-Phenylpropyl)-1,4,2-dioxazol-5-one 4i Using a Microwave Reactor (1 mmol Scale). With a benchtop setup, to a flame-dried 10−20 mL Biotage microwave vial (#354833) charged with a stir bar was added *N*-imidazo imine **1a** (171 mg, 1.00 mmol, 1.00 equiv), $[Cp^*Rh(MeCN)_3](SbF_6)_2$ (10 mol %, 0.100 mmol, 83.3 mg), PivOH (204 mg, 2.00 mmol, 2 equiv), and NaOAc (41.0 mg, 0.500 mmol, 0.500 equiv). The vial was capped with a Teflon-lined cap and flushed with N_2 for ca. 5 min, and then, dioxane (10.0 mL, 0.100 M) was added. To the resulting mixture was added 3-(3-phenylpropyl)-1,4,2-dioxazol-5-one **4i** (0.260 mL, 306 mg, 0.450 mmol, 1.50 equiv) dropwise via syringe. The reaction vial was flushed with N_2 for a further ca. 5 min before heating with a Biotage Initiator+ (#356007), which employs an external IR sensor and a closed reaction vessel. The resultant mixture was stirred in the microwave reactor for 2 h at 170 °C using the following settings (absorption level, low; vial type, 10−20 mL; prestirring, 0; initial power, 0; dynamic deflector optimization, ON; pressure: OFF; power, OFF; fixed hold time, ON; stir rate, 600). After cooling to rt, the resultant mixture was filtered through a pad of Celite, washed thoroughly with acetone, and concentrated under reduced pressure. Purification by silica gel column chromatography (5−35% acetone/hexanes) afforded **6ai** (205.3 mg, 65%) as an off-white solid. ^1H and ^{13}C NMR spectra matched with **6ai** obtained from a small scale (0.3 mmol).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.8b01249.

NMR spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: jonathan.ellman@yale.edu.

ORCID

Gia L. Hoang: 0000-0003-2332-1854

Jonathan A. Ellman: 0000-0001-9320-5512

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the NIH (R35GM122473 to J.A.E.). The Villum Foundation (VKR023371) is also acknowledged for postdoctoral support to K.S.H.

■ REFERENCES

(1) For selected approved drugs incorporating a [5,6]-bicyclic heterocycle core with a ring junction nitrogen, see: anagliptin, olprinone, minodronic acid, vardenafil, zalepton, acalabrutinib, zolpidem, and ponatinib. The compound structure, bioactivity, list of literature, and access to ongoing clinical trials, applications, and usage can be obtained by searching the compound name in PubChem.

(2) For select phase II and III clinical candidates incorporating a [5,6]-bicyclic heterocycle core with a ring junction nitrogen, see: LY2090314, dipraglurant, AMG-337, irbinitinib, dinaciclib, empesertib, fligotinib, entospletinib, and volitinib. The compound structure, bioactivity, list of literature, and access to ongoing clinical trials, applications, and usage can be obtained by searching the compound name in PubChem.

(3) Halskov, K. S.; Witten, M. R.; Hoang, G. L.; Mercado, B. Q.; Ellman, J. A. Rhodium(III)-Catalyzed Imidoyl C−H Activation for Annulations to Azolopyrimidines. *Org. Lett.* **2018**, *20*, 2464−2467.

(4) For selected reviews on transition-metal-catalyzed C−H functionalization that include applications to nitrogen heterocycle synthesis, see: (a) Satoh, T.; Miura, M. Oxidative Coupling of Aromatic Substrates with Alkynes and Alkenes under Rhodium Catalysis. *Chem. - Eur. J.* **2010**, *16*, 11212−11222. (b) Song, G.; Wang, F.; Li, X. C−C, C−O and C−N Bond Formation via Rhodium(III)-Catalyzed Oxidative C−H Activation. *Chem. Soc. Rev.* **2012**, *41*, 3651−3678. (c) Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. C−H Bond Functionalization: Emerging Synthetic Tools for Natural Products and Pharmaceuticals. *Angew. Chem., Int. Ed.* **2012**, *51*, 8960−9009. (d) Mesganaw, T.; Ellman, J. A. Convergent Synthesis of Diverse Tetrahydropyridines via Rh(I)-Catalyzed C−H Functionalization Sequences. *Org. Process Res. Dev.* **2014**, *18*, 1097−1104. (e) Gulías, M.; Mascareñas, J. L. Metal-Catalyzed Annulations through Activation and Cleavage of C−H Bond. *Angew. Chem., Int. Ed.* **2016**, *55*, 11000−11019. (f) Newton, C. G.; Wang, S.-G.; Oliveira, C. C.; Cramer, N. Catalytic Enantioselective Transformations Involving C−H Bond Cleavage by Transition-Metal Complexes. *Chem. Rev.* **2017**, *117*, 8908−8976. (g) Hummel, J. R.; Boerth, J. A.; Ellman, J. A. Transition-Metal-Catalyzed C−H Bond Addition to Carbonyls, Imines, and Related Polarized π Bonds. *Chem. Rev.* **2017**, *117*, 9163−9227. (h) Park, Y.; Kim, Y.; Chang, S. Transition Metal-Catalyzed C−H Amination: Scope, Mechanism, and Applications. *Chem. Rev.* **2017**, *117*, 9247−9301. (i) Dong, Z.; Ren,

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX−XXX

Z.; Thompson, S. J.; Xu, Y.; Dong, G. Transition-Metal-Catalyzed C−H Alkylation Using Alkenes. *Chem. Rev.* **2017**, *117*, 9333−9403.
(5) Sauer, J.; Mayer, K. K. Thermolyse und Photolyse von 3.4-Diphenyl-Δ^2-1.2.4-oxdiazolinon-(5) und 2.4-Diphenyl-Δ^2-1.3.4-oxdiazolinon-(5). *Tetrahedron Lett.* **1968**, *9*, 319−324.
(6) Dubé, P.; Nathel, N. F. F.; Vetelino, M.; Couturier, M.; Aboussafy, C. L.; Pichette, S.; Jorgensen, M. L.; Hardink, M. Carbonyldiimidazole-Mediated Lossen Rearrangement. *Org. Lett.* **2009**, *11*, 5622−5625.
(7) Bizet, V.; Buglioni, L.; Bolm, C. Light-Induced Ruthenium-Catalyzed Nitrene Transfer Reactions: A Photochemical Approach towards *N*-Acyl Sulfimides and Sulfoximines. *Angew. Chem., Int. Ed.* **2014**, *53*, 5639−5642.
(8) (a) Park, Y.; Park, K. T.; Kim, J. G.; Chang, S. Mechanistic Studies on the Rh(III)-Mediated Amido Transfer Process Leading to Robust C−H Amination with a New Type of Amidating Reagent. *J. Am. Chem. Soc.* **2015**, *137*, 4534−4542. (b) Park, Y.; Jee, S.; Kim, J. G.; Chang, S. Study of Sustainability and Scalability in the Cp*Rh(III)-Catalyzed Direct C−H Amidation with 1,4,2-Dioxazol-5-ones. *Org. Process Res. Dev.* **2015**, *19*, 1024−1029.
(9) For a recent review including 1,4,2-dioxazol-5-one as an efficient amidating reagent in C−H functionalization, see ref 4h and references cited therein.
(10) Halskov, K. S.; Roth, H. S.; Ellman, J. A. Synthesis of [5,6]-Bicyclic Heterocycles with a Ring-Junction Nitrogen Atom: Rhodium-(III)-Catalyzed C−H Functionalization of Alkenyl Azoles. *Angew. Chem., Int. Ed.* **2017**, *56*, 9183−9187.
(11) Wu, X.; Sun, S.; Xu, S.; Cheng, J. Rh-Catalyzed Annulation of *ortho*-C−H Bonds of 2-Arylimidazoles with 1,4,2-Dioxazol-5-ones toward 5-Arylimidazo[1,2-*c*]quinazolines. *Adv. Synth. Catal.* **2018**, *360*, 1111−1115.
(12) Lim, F. P. L.; Dolzhenko, A. V. 1,3,5-Triazine-Based Analogues of Purine: From Isosteres to Privileged Scaffolds in Medicinal Chemistry. *Eur. J. Med. Chem.* **2014**, *85*, 371−390.
(13) Li reported that $Zn(OAc)_2$ in conjunction with a cobalt catalyst provides an efficient system for annulations to enamides and pyrimidones. See: Liu, Y.; Xie, F.; Jia, A.-Q.; Li, X. Cp*Co(III)-Catalyzed Amidation of Olefinic and Aryl C−H Bonds: Highly Selective Synthesis of Enamides and Pyrimidones. *Chem. Commun.* **2018**, *54*, 4345−4348. Co(III) and Rh(III) catalysts employed with $Zn(OAc)_2$ instead of NaOAc/PivOH were tried but proved unsuccessful: no desired bicyclic product was detected by crude ^{1}H NMR.
(14) Li, H.; Zhao, J.; Zeng, L.; Hu, W. Organocatalytic Asymmetric Domino Aza-Michael−Mannich Reaction: Synthesis of Tetrahydroimidazopyrimidine Derivatives. *J. Org. Chem.* **2011**, *76*, 8064−8069.
(15) (a) Mishra, A.; Mukherjee, U.; Vats, T. K.; Deb, I. Ir(III)/MPAA-Catalyzed Mild and Selective C−H Amidation of *N*-Sulfonyl Ketimines: Access to Benzosultam-Fused Quinazolines/ Quinazolinones. *J. Org. Chem.* **2018**, *83*, 3756−3767. (b) Chen, Y.; Zhang, R.; Peng, Q.; Xu, L.; Pan, X. Rhodium(III)-Catalyzed Directed C−H Amidation of *N*-Nitrosoanilines and Subsequent Formation of 1,2-Disubstituted Benzimidazoles. *Chem. - Asian J.* **2017**, *12*, 2804−2808. (c) Bizet, V.; Bolm, C. Sulfur Imidations by Light-Induced Ruthenium-Catalyzed Nitrene Transfer Reactions. *Eur. J. Org. Chem.* **2015**, *2015*, 2854−2860.
(16) Little, T. L.; Webber, S. E. A Simple and Practical Synthesis of 2-Aminoimidazoles. *J. Org. Chem.* **1994**, *59*, 7299−7305.
(17) Usachova, N.; Leitis, G.; Jirgensons, A.; Kalvinsh, I. Synthesis of Hydroxamic Acids by Activation of Carboxylic Acids with *N,N′*-Carbonyldiimidazole: Exploring the Efficiency of the Method. *Synth. Commun.* **2010**, *40*, 927−935.

DOI: 10.1021/acs.joc.8b01249
J. Org. Chem. XXXX, XXX, XXX−XXX